AXSM — Axsome Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1579428 ·
Last close
$195.09
Market Cap
$10.22B
52W High
$260.19
52W Low
$115.72
ADV30
589,110
Next earnings
2026-11-02

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 218,375,000 204,811,000 -51,142,000 -51,314,000 761,447,000 319,850,000 678,143,000
Mar 2026 191,203,000 176,478,000 -62,767,000 -64,542,000 713,607,000 305,106,000 659,020,000
Dec 2025 195,999,000 183,670,000 -36,025,000 -28,559,000 689,805,000 322,933,000 601,510,000
Sep 2025 170,992,000 159,080,000 -32,924,000 -47,229,000 669,250,000 325,272,000 595,523,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-70,730,000
Investing CF
$-263,000
Financing CF
$75,189,000
CapEx
$-263,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.73
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,370,503,000
Inventory
$31,515,000
Receivables
$251,062,000
ST Investments
—
EBIT TTM
$-183,522,000
Pretax Income TTM
$-188,833,000
Interest Exp TTM
$5,311,000
Analysts
21

Yahoo Snapshot (yfinance, live)

Total Revenue
$776,569,024
EBITDA
$-172,919,008
Free Cash Flow
$-4,581,750
Enterprise Value
$11,467,908,096
Total Cash
$319,849,984
Total Debt
$224,692,992
Shares Out
52,380,818
Trailing EPS
$-3.75
Book Value
$1.59
ROE
-245.1%
ROA
-16.3%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 638,496,000 -169,235,000 -183,174,000 689,805,000 601,510,000 88,295,000 -93,405,000
Dec 2024 385,693,000 -252,438,000 -287,216,000 568,498,000 511,483,000 57,015,000 -128,410,000
Dec 2023 270,600,000 -182,907,000 -239,238,000 588,236,000 397,259,000 190,977,000 -145,080,000
Dec 2022 50,037,000 -176,501,000 -187,134,000 331,476,000 221,920,000 109,556,000 -116,511,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$5.03

Max Pain — expiry 2027-01-15

max pain strike: $170.00 · spot: $196.21 · call oi: 7,771 · put oi: 8,096
Expected Move to 2027-01-15: ±$35.50 (18.09%) — implied range $160.71 – $231.71 · ATM straddle on $195.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
RDY DR REDDYS LABORATORIES LTD $10.20B $12.25 —
ELAN Elanco Animal Health Inc $11.14B $22.31 —
ARWR ARROWHEAD PHARMACEUTICALS, INC. $9.31B $65.92 —
PTGX Protagonist Therapeutics, Inc $9.18B $141.86 —
CYTK CYTOKINETICS INC $8.99B $64.66 —

News headlines (Yahoo Finance, 1h cache)

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
2026-09-21 11:00 · Yahoo
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction
2026-09-19 18:02 · Yahoo
Axsome Therapeutics (AXSM) Stock Looks Undervalued As Its 5 Year 7x Run Continues
2026-09-19 13:11 · Yahoo
Is Axsome Therapeutics’ (AXSM) New CNS Data Enough To Reinforce Its Neuropsychiatric Portfolio Story?
2026-09-19 11:14 · Yahoo
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference
2026-09-19 08:02 · Yahoo
Axsome Therapeutics (AXSM) Reported New Clinical Data In Depression And Alzheimer’s Agitation
2026-09-19 04:18 · Yahoo
Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?
2026-09-18 22:22 · Yahoo
Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
2026-09-18 19:25 · Yahoo
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
2026-09-18 13:00 · Yahoo
Is Axsome Therapeutics a Buy on the Dip?
2026-09-18 07:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.